ONDINE BIOMEDICAL INC.CDI (VF5) - Total Assets
Based on the latest financial reports, ONDINE BIOMEDICAL INC.CDI (VF5) holds total assets worth €12.82 Million EUR (≈ $14.99 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore VF5 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
ONDINE BIOMEDICAL INC.CDI - Total Assets Trend (2021–2024)
This chart illustrates how ONDINE BIOMEDICAL INC.CDI's total assets have evolved over time, based on quarterly financial data. See net assets of ONDINE BIOMEDICAL INC.CDI for net asset value and shareholders' equity analysis.
ONDINE BIOMEDICAL INC.CDI - Asset Composition Analysis
Current Asset Composition (December 2024)
ONDINE BIOMEDICAL INC.CDI's total assets of €12.82 Million consist of 95.1% current assets and 4.9% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 76.2% |
| Accounts Receivable | €458.00K | 3.6% |
| Inventory | €1.27 Million | 9.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how ONDINE BIOMEDICAL INC.CDI's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ONDINE BIOMEDICAL INC.CDI (VF5) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ONDINE BIOMEDICAL INC.CDI's current assets represent 95.1% of total assets in 2024, a decrease from 98.1% in 2021.
- Cash Position: Cash and equivalents constituted 76.2% of total assets in 2024, down from 88.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is inventory at 9.9% of total assets.
ONDINE BIOMEDICAL INC.CDI Competitors by Total Assets
Key competitors of ONDINE BIOMEDICAL INC.CDI based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
SL Science Holding Limited Ordinary Shares
NASDAQ:SLBT
|
USA | $2.82 Million |
|
REMEGEN CO. LTD YC 1
F:REG
|
Germany | €7.25 Billion |
ONDINE BIOMEDICAL INC.CDI - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.05 | 0.80 | - |
| Quick Ratio | 1.84 | 0.48 | - |
| Cash Ratio | 0.00 | 0.00 | - |
| Working Capital | €6.24 Million | €-784.00K | - |
ONDINE BIOMEDICAL INC.CDI - Advanced Valuation Insights
This section examines the relationship between ONDINE BIOMEDICAL INC.CDI's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 16.47 |
| Latest Market Cap to Assets Ratio | 5.88 |
| Asset Growth Rate (YoY) | 123.6% |
| Total Assets | €12.82 Million |
| Market Capitalization | $75.33 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values ONDINE BIOMEDICAL INC.CDI's assets at a significant premium (5.88x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: ONDINE BIOMEDICAL INC.CDI's assets grew by 123.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ONDINE BIOMEDICAL INC.CDI (2021–2024)
The table below shows the annual total assets of ONDINE BIOMEDICAL INC.CDI from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €12.82 Million ≈ $14.99 Million |
+123.61% |
| 2023-12-31 | €5.73 Million ≈ $6.70 Million |
-65.39% |
| 2022-12-31 | €16.57 Million ≈ $19.37 Million |
-51.47% |
| 2021-12-31 | €34.14 Million ≈ $39.91 Million |
-- |
About ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more